Please assess the completion status of the following clinical trial:

Trial Title: Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18 years~* Histologically proven cutaneous lupus erythematosus with or without associated systemic disease~* Presence of at least a grade II erythema as assessed by the validated modified Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI)~* Cutaneous lesions involving more than 18% of the body surface calculated according to the rule of the nines, or history of severe side effects or lack of efficacy following thalidomide therapy, in cutaneous lupus disease refractory to conventional treatment with antimalarials and topical steroids.~* No pregnancy or wish to become pregnant during the study period.~Exclusion Criteria:~* Pregnancy, breastfeeding or the use of not adequate contraception.~* Severe thrombocytopenia (\<30x10E9 cells/L) or leucopoenia (\<1500x10E9), known at least 30 days prior to the onset of the study,~* Previous history of arterial/venous thrombosis,~* Presence of antiphospholipid antibodies~* Presence of moderate-severe renal impairment (FG \<30 ml/min)~* Progressive renal disease.~* Lack of written informed consent prior to participation in the study.~* Presence of a concomitant systemic flare that may require other systemic treatments for its control~* Any psychiatric o social disease that may interfere with the study and follow-up~* HIV, B or C hepatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lenalidomide Group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).